Full-Time

Process Development Engineer

Manufacturing Technology & Transfer

Posted on 9/12/2025

Illumina

Illumina

5,001-10,000 employees

Accelerates genomics startups through funding

Compensation Overview

$73.4k - $110.2k/yr

+ Bonus + Commission + Equity

No H1B Sponsorship

San Diego, CA, USA

In Person

Category
Mechanical Engineering (1)
Required Skills
GD&T
Requirements
  • Experience with consumable design and fabrication, assembly process development, working with global contract manufacturing houses
  • Ability to read and interpret mechanical engineering drawings, GD&T experience is a plus
  • Ability to evaluate First Article Inspection, propose improvements to enhance quality and work with external vendors to implement changes
  • Experience with product development processes, design transfer and process and equipment validation
  • Experience with Statistics, Statistical Process Control and DOE techniques is a plus, High level problem solving, and reasoning skills required
  • Experience with cGMP and 21 CFR part 11 and supporting manufacturing in an FDA regulated environment is preferred
  • Effective communication skills both verbal and written, analytical and organizational skills to manage competing project priorities
  • Experience with high volume production in a high tech, high volume consumables industry is a plus
  • High level computer skills are required. Intermediate level programming knowledge is a plus
  • Experience with product development processes and project management is a plus
  • Demonstrated ability to accomplish goals while working across departments is required
Responsibilities
  • Participate in consumable product development, manufacturing process development, process and product improvements, and other activities in the making of consumable products to sequence genomes
  • Represent Operations needs on development teams for effective transfer of products into manufacturing
  • Define technical requirements for manufacturing processes and new production equipment
  • Author procedures and instructions for new manufacturing processes and train production operators to manufacture product in a GMP environment
  • Design, develop and source production equipment from vendors and OEM’s, work cross functionally with EHS and Facilities to establish safe production processes to enable manufacturing of consumable products
  • Troubleshoot new product and manufacturing process issues related to yield, quality and throughput
  • Develop understanding of CPM (critical parameter management), construct and execute controlled experiments and including DOE's to optimize processes, address yield and quality issues and drive implementation of solutions into a production environment to meet project goals
  • Analyze process test results, issue reports and make technical recommendations to improve product and process quality
  • Utilize expertise in 6-sigma, DFSS, 8D, DMAIC to solve issues that arise during product and process development phases of new product introductions
  • Work cross functionally with Product Development, Supply Chain, Manufacturing, Quality teams to enable operations for both launch and high-volume manufacturing
  • Ensure successful transfer of knowledge into manufacturing and the sustaining support teams
Desired Qualifications
  • Experience with Statistics, Statistical Process Control and DOE techniques is a plus
  • Experience with cGMP and 21 CFR part 11 and supporting manufacturing in an FDA regulated environment is preferred
  • Experience with high volume production in a high tech, high volume consumables industry is a plus
  • High level computer skills are required. Intermediate level programming knowledge is a plus
  • Experience with product development processes and project management is a plus

Illumina Accelerator helps create and grow genomics startups by partnering with venture investors and entrepreneurs as part of Illumina for Startups. It runs as a company-creation engine co-located with Illumina’s R&D sites in the San Francisco Bay Area and Cambridge, UK, offering mentorship, resources, and access to Illumina’s technology and networks. Its edge comes from Illumina’s sequencing tech, R&D resources, and a global network, plus a track record of 68 funded startups that have raised over $1 billion. The goal is to support ideas turning into market-ready genomics products and companies.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Clinical sequencing drives 65% of consumables revenue in Q1 2026.
  • D3b partnership analyzes 100,000 pediatric genomes for rare disease research.
  • USDA-FSIS adopts MiSeq i100 for foodborne pathogen WGS starting May 2026.

What critics are saying

  • Element Biosciences AVITI undercuts NovaSeq pricing by 70-80% per gigabase.
  • MGI Tech DNBSEQ captures 25% China market and expands globally.
  • Ultima Genomics UG 100 delivers 70% lower cost per genome at scale.

What makes Illumina unique

  • Illumina generates over 90% of world's DNA sequencing data.
  • NovaSeq X platform placed over 80 units in Q1 2026.
  • DRAGEN v4.5 reduces oncology false positives by over 90%.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
PR Newswire
Apr 14th, 2026
Illumina and D3b unite 100,000 pediatric genomes to accelerate rare disease and cancer research

Illumina and the Center for Data-Driven Discovery in Biomedicine have announced a data partnership to advance paediatric cancer and rare disease research. D3b is analysing 100,000 whole genomes from paediatric patients using Illumina software solutions, creating one of the largest unified genomic datasets ever assembled. The resulting insights will be made available through the Gabriella Miller Kids First Data Resource Centre, enabling researchers and clinicians to uncover biological origins of rare diseases and cancers. The dataset includes whole genomes from patients with rare congenital conditions and cancers, analysed using DRAGEN v4.4 and Illumina Connected Analytics. Additionally, Illumina is supporting D3b in the Pediatric Care eXpansion programme, which aims to reduce patient care journeys from months to weeks through a national data exchange spanning over 200 US paediatric institutions.

Food Safety Magazine
Apr 13th, 2026
USDA-FSIS updates WGS laboratory method.

USDA-FSIS updates WGS laboratory method. April 13, 2026 The U.S. Department of Agriculture's Food Safety and Inspection Service (USDA-FSIS) has updated its whole genome sequencing (WGS) laboratory method to incorporate the Illumina MiSeq i100 sequencing platform. MiSeq i100 represents the next generation of MiSeq sequencing instrumentation featuring integrated sequencing chemistry and substantially reduced runtimes. FSIS reports that this modernization enhances its laboratory system's ability to generate consistent, high-quality genomic data with increased laboratory sample throughput. The updated Microbiology Laboratory Guidebook (MLG) chapter 42, "Whole Genome Sequencing of Bacterial Isolates," now includes protocols for using both the Illumina MiSeq and MiSeq i100 platforms. FSIS will begin integrating the MiSeq i100 platform starting in May 2026, through the remainder of the fiscal year as existing laboratory supplies are exhausted and additional i100 units come online across FSIS laboratories. The current MiSeq instrumentation remains fully valid and equivalent for WGS analyses and will continue to be used where appropriate. WGS determines the full DNA sequence of an organism in a single laboratory protocol, and FSIS performs WGS on every bacterial isolate obtained from regulated food product and environmental samples. This publicly available data supports foodborne pathogen monitoring, food safety research, and other regulatory applications. FSIS notes that the inclusion of a specific commercial product in the MLG should not be considered an endorsement by the agency. Looking for quick answers on food safety topics? Try Ask FSM, our new smart AI search tool. Ask FSM SPONSORED BY Hi there. I'm Ask FSM. You can ask me anything about science-based solutions f The Food Safety Magazine editorial team comprises Bailee Henderson, Digital Editor | and Adrienne Blume, M.A., Editorial Director. JOIN TODAY to unlock your recommendations. Already have an account? Sign In

Yahoo Finance
Apr 9th, 2026
Illumina shares up 31.7% since October despite declining organic revenue and mediocre ROIC

Illumina has gained 31.7% since October 2025, reaching $126.99 per share, outpacing the S&P 500's 1.8% decline. Despite this performance, analysts cite three concerns about the genomics company. Illumina's organic revenue has declined an average of 1.1% year-on-year over the past two years, suggesting weakness in its core business. The company's earnings per share grew just 1.5% annually over five years, below its 6% revenue growth, indicating decreasing profitability. Additionally, its five-year average return on invested capital of 0.3% falls below typical healthcare sector costs. Trading at 24.7× forward price-to-earnings, the stock may present excessive downside risk despite recent gains, according to the analysis.

PR Newswire
Apr 2nd, 2026
Illumina board changes: Arnold, Epstein and Guthart to retire, King nominated

Illumina has announced changes to its board of directors ahead of its annual shareholder meeting. Frances Arnold, Robert S. Epstein and Gary S. Guthart will retire from the board, whilst the company has nominated David P. King for election as a new member. King brings extensive healthcare and life sciences experience as former executive chairman and CEO of Laboratory Corporation of America Holdings. He currently serves as director and chair of Privia Health and AmSurg Corporation, and as director of Smith & Nephew. Before joining LabCorp in 2001, King was a partner at Hogan & Hartson, where he led the firm's healthcare fraud and abuse practice. Board chair Scott Gottlieb praised the retiring directors' service and highlighted King's operating experience and regulatory insight across healthcare and life sciences.

Illumina
Mar 27th, 2026
Connect with Illumina at a major cancer research conference.

Connect with Illumina at a major cancer research conference. Details. Illumina will be exhibiting at the American Association for Cancer Research(R)(AACR) Annual Meeting 2026 in San Diego. Not affiliated with or endorsed by AACR. Learn how Illumina is driving innovation in cancer research and clinical solutions. Discover our latest advancements in single-cell, spatial, and multiomics technologies for research, and connect with our experts to learn about our cutting-edge IVD clinical testing solutions. Come explore our newest, disruptive single-cell and multiomics methods, designed to unlock game-changing discoveries in cancer research. Our booth and spotlight talk will showcase high-resolution microenvironment characterization and multiomics analysis methods that deliver deeper insights, without specialized equipment and at a fraction of the cost of alternative methods. Connect with our team to discover how these scalable technologies can accelerate every stage of cancer research and explore IVD clinical testing solutions available to your institution. Visit us at Illumina booth 4727 to learn more about how Illumina can help advance your research and clinical solutions. Schedule of Illumina events. Sunday, April 19. Exhibitor Spotlight Theater 1:30 PM-2:30 PM (PT) From circulating signals to spatial context: Multiomic insights for next-generation cancer research Location: Illumina Spotlight Theater B Multiomics is advancing cancer research at an unprecedented scale, opening new ways to understand disease and improving how we detect and track it. This symposium brings together two exciting areas driving that progress: multiomic liquid biopsy, combining DNA and methylation signals for deeper biological insights into disease detection and progression, and spatial transcriptomics, which helps reveal how cells are organized and interact within the tumor microenvironment (TME). We will share updates on Illumina innovations that connect these layers of biology, along with customer examples in 5-base, methylation-aware liquid biopsy, and spatially resolved expression mapping. Join us to explore how integrated multiomics can sharpen detection, bring tumor ecosystems into a clearer view, and accelerate translational discoveries. Featured speakers David Spencer, MD, PhD Assoc Professor, Division of Oncology Washington University School of Medicine Claire Mills, DDS, PhD Oral Health Sciences, University of Washington Fred Hutchinson Cancer Center, Setty & Beronja Labs Richard Capper, PhD Sr Director, Global Research Customer Marketing Illumina This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater are the opinions of the presenter and do not represent the position or the opinion of the American Association for Cancer Research(R)(AACR) or its members. Exhibit hours. Illumina booth 4727 * Sunday, April 19: 12 noon-5 PM (PT) * Monday, April 20: 9 AM-5 PM (PT) * Tuesday, April 21: 9 AM-5 PM (PT) * Wednesday, April 22: 9 AM-12 noon (PT) * Date & Time - Apr 19, 2026 - Apr 22, 2026 * Location - San Diego Convention Center Illumina booth 4727 San Diego, California * Topic - Cancer research, Oncology

INACTIVE